The 2009 RCVS Continuing Professional Development Record Cards have been sent to all practising vets and Registered Veterinary Nurses.
Undertaking and recording Continuous Professional Development (CPD) is a mandatory professional requirement for these vets and RVNs. Vets must average at least 35 hours of CPD per year and RVNs 15 hours, although many will do far more.
The RCVS can ask to see CPD records - and they may be checked during practice inspections as part of the Practice Standards Scheme. For newly-qualified veterinary surgeons, completing the Professional Development Phase also fulfils the CPD requirements in their first year of practice.
Jill Nute, President of the RCVS, said: "CPD is about maintaining professional competence. Vets and RVNs are expected to make continuous improvements in their knowledge and skills, which will have benefits for their patients and clients, their own development and the profession at large. Undertaking CPD allows vets and RVNs to demonstrate their commitment to maintaining the highest professional standards."
As professionals, vets and RVNs are expected to evaluate what knowledge and skills they need to develop, and how they will do this. This may include activities such as going to particular case-conferences or asking for some in-house training. Getting together with other practices to organise training sessions or secondments or finding a mentor can also be useful.
Personal study - documented in a learning diary detailing the aims of the study, what was studied and the outcomes, for example, a change made to a practice protocol - can also be used. There is no limit on properly documented study, but vets cannot count more than 10 hours, and veterinary nurses five hours, each year of undocumented study.
All CPD activity should be systematically planned to meet identified professional needs, and clear records must be kept of what has been done.
Further information about CPD requirements for veterinary surgeons and Registered Veterinary Nurses can be found on the back of the CPD Record Card, and at RCVSonline (www.rcvs.org.uk).
Woodley Equipment Co Ltd has announced that it has been appointed by Synermed International as the exclusive distributor in the UK & Europe for the IR202 Series Near-Infrared Biochemistry reagents.
Woodley will supply regular maintenance visits, support and a monthly supply of reagents to IR202 analyser customers.
For further information, visit www.woodleyequipment.com, www.synermedinc.com, email sales@woodleyequipment.com or telephone 01798 813659.
Dairy vets will soon be receiving a DVD highlighting the economic losses due to coccidiosis in cattle, from Janssen Animal Health.
According to the company, coccidiosis is a major cause of scouring and poor growth rates in calves yet recent findings have demonstrated that a massive 61 per cent of the economic loss occurs in sub-clinically infected calves that are not showing any obvious clinical signs. Treated calves have been shown to put on 20 per cent more weight than untreated calves1. Coccidiosis infects between 16 and 27 per cent of adult cattle who act as reservoirs of the disease2,3,4,5. This means that most calves are likely to become exposed to the infectious form of the parasite. After the age of 6 months the majority of calves acquire immunity but if they are exposed to a massive challenge before that time due to large numbers of the coccidial oocysts or due to a stress factor, sub-clinical or clinical disease occurs.
The DVD describes the challenges involved in diagnosing coccidiosis and how to interpret faecal oocyst counts, as well as some of the characteristics of sub-clinical infection in calves. The benefits of metaphylactic and preventative approaches to treatment with Vecoxan®, the only anticoccidial drench licensed for beef and dairy cattle at any age, indoors and out, are discussed.
Nigel Underwood from Janssen Animal Health said: "The diagnosis of non-specific scour is problematic at best but it is important that vets have coccidiosis at front of mind when considering the differential diagnosis. Prompt treatment of the whole batch of calves can stop the disease in its tracks and does not interfere with the development of future immunity. We hope this DVD will provide an update on the latest thinking and help increase recognition of this disease."
The DVD will be sent out in February and any vet with an interest in the disease who does not received one before the end of the month should call Janssen on 01494 567555 to request a copy.
Further information is available from Janssen Animal Health, 50-100 Holmers Farm Way, High Wycombe, Bucks, HP12 4EG Tel 01494 567555 Fax 01494 567556 Email: ahealth@jacgb.jnj.com
References
Bayer has introduced a new microchip scanner which is capable of reading all chips, including encrypted ones.
The company says the new Tracer Advance Isomax V scanner offers exceptional reading distances of more than twice those of other scanners on the market, making it a very versatile tool ideally suited for use in companion animal practices or for detecting microchips in larger animals such as horses.
The technology that gives this scanner its backward compatibility with non ISO standard chips means practices can now save money by only having to buy one scanner, whereas previously two were required to be able to read all types of chip.
Other features of the device include digital signal processing (DSP), which protects against radio interference from TVs and PCs, and connectivity via USB, RS232 or optional Bluetooth interface.
The Tracer Advance Isomax V scanner is available from Bayer and is priced at £499.95. It comes with a 30-month warranty. Contact your Bayer territory representative for further details.
The RCVS and the Veterinary Medicines Directorate (VMD) will be holding a free Masterclass offering practical guidance on the requirements of the Veterinary Practice Premises Register, on Saturday 4 April, at BSAVA Congress.
If you are concerned about medicines inspections and would like further information about complying, this is your chance to find out what you need to do.
By 1 April, all practice premises from which medicines are supplied should be registered with the RCVS. All such premises are then subject to inspection - by either Practice Standards Scheme inspectors, if accredited under the Scheme, or VMD inspectors. Will you be ready if an inspector calls?
Suitable for veterinary surgeons, veterinary nurses and practice managers, the interactive session will be held from 10am - 12noon, with presentations from VMD and the Chief Inspector of the Practice Standards Scheme, followed by group discussion and plenty of time for questions and answers.
Attendance at the Masterclass, which will be held in Hall 6 of the ICC in Birmingham, is free to BSAVA passholders.
For your free ticket, contact Fiona Harcourt on 020 7202 0773, f.harcourt@rcvs.org.uk, or during Congress visit the RCVS Stand, number 918, opposite the catering stand in the Exhibition hall.
Genitrix has announced that HY-50 Vet®, a sodium hyaluronate treatment for equine joints, has now been authorised for intravenous (IV) use.
Available until now for intra-articular (IA) use only, the company says HY-50 delivers the highest concentration of sodium hyaluronate on the market for the treatment of non-infectious joint inflammation and the enhancement of joint function.
Genitrix also says that, as IV application requires less specialist preparation than IA, HY-50 is now a practical solution for mixed practices with a smaller equine case load. Injected intravenously, the product will also benefit horses with multiple joint injuries.
HY-50 is presented in a 3 ml pre-loaded syringe, delivering 50 mg of sodium hyaluronate. It costs £55.50.
Rob Watkins, Marketing Director of Genitrix, said: "The efficacy of sodium hyaluronate is well established and we're delighted to be able to offer the IV route of administration. We know it will meet a real need in the market for a lameness treatment which is proven and simple to administer."
"Perhaps most importantly, in these financially difficult times, the high concentration of the product makes it a cost-effective approach compared with competitive products. We believe it will offer an affordable treatment option for owners who are anxious to treat their horses but may be discouraged by the high cost of many treatments."
For further information, see http://www.genitrix.co.uk/ or ring 01403 786345.
A new long acting sheep injection has been launched by Fort Dodge Animal Health which the company says will offer significant benefits to sheep farmers for both internal and external parasite control.
Cydectin 2% LA for sheep is the latest product to join the Cydectin range and follows the long acting injection for cattle.
Based on Moxidectin, the product delivers a long action against worms, up to 111 days and scab, 60 days from a single injection.
Andrew Wylie from Fort Dodge said: "To put this into context, apart from the existing Cydectin range which lasts up to 35 days, no other product is licensed with persistent activity against worms and scab. Cydectin 2% LA for sheep offers three times the worm cover and double the scab cover from a single injection.
"Therefore farmers will benefit from Cydectin 2% LA through the combination of a single injection with extended persistency leading to a reduction in the number of treatments needed for worms and scab and the potential increase in lamb weight gain due to a lower worm and scab challenge."
Fort Dodge recommends the following three key uses for Cydectin 2% LA given the persistent effect and single shot:
Administration is by a single sub-cutaneous injection high up the neck at the base of the ear which is designed to limit the withhold period to 104 days. The technique is not difficult and, if used with the multidose applicator supplied, farmers will find it a straightforward procedure.
Cydectin 2% LA is available in 50ml, 200ml and 500ml bottles and with a dose rate of 1ml per 20kg, a 500ml pack will treat 200 sheep at 50kg. For further, call Fort Dodge on 01489 781711.
According to the results of DairyCheck 2008, Intervet/Schering-Plough Animal Health's subsidised milk testing service, 65% of herds tested positive for IBR infection, 69% positive for Leptospirosis and the majority of herds tested showed evidence of previous BVD exposure.
According to Intervet/Schering Plough, it is widely known that exposure levels of these three endemic diseases are high, yet many producers don't see the hidden losses. Making use of DairyCheck can demonstrate infection levels on an individual unit and help encourage a control and management programme to be put in place
Vet adviser Ruth Vernon said: "It can be a case of 'out of sight, out of mind'. After the initial infection, cows may appear healthy, but be suffering from the effects of immune suppression as a result of BVD virus infection. This results in herd performance that is often below expected levels."
"When the news is good - and on average around 33% of DairyCheck tested herds were found to be clear of all three diseases - farmers need guidance and advice on keeping a naïve herd clear of disease.
"Taking time to explain how to incorporate biosecurity measures on a day-to-day basis as well as quarantine and vaccination programmes can significantly improve the health status of previously infected units."
Further information on DairyCheck is available from Intervet/Schering-Plough Account Managers.
Janssen Animal Health has launched a range of skincare products - Cavalesse® and Cavalesse® Topical - to help maintain and support a healthy skin in horses prone to summer skin allergies.
According to the company, summer skin allergies, including sweet itch, which is caused by reactions to bites from Culicoides midges, can be serious and frustrating conditions that affect three to five per cent of all horses in the UK. These allergies can be difficult to manage and are often a real challenge for both horse owners and vets alike.
Cavalesse is a natural food supplement containing a specialised formulation of water-soluble vitamins and minerals, including Nicotinamide. Once a month the contents of each sachet are dissolved in water to form an oral solution, which can be administered daily via a special pipette, either by sprinkling over a small handful of feed or adding to a treat such as a sugar lump. The supplement helps horses maintain a healthy skin by reducing histamine release within the skin, moderating the excessive immune response within the skin, reducing anti-inflammatory reactions and suppressing antigen induced transformation.
To complete the Cavalesse skin management range, Cavalesse Topical is a skincare gel that can be used in combination with the Cavalesse solution. The gel can be applied to the skin to help support natural immunity from the outside, whilst the oral solution works in partnership from the inside.
Helen Goldberg, marketing manager at Janssen Animal Health said: "Summer skin allergies, such as sweet itch, are frustrating conditions that can be difficult to treat. To help prevent the disease, horses are often fully blanketed while out at grass, given limited access to pasture or covered with insect repellents, while treatment has included antihistamines and corticosteroids which can have side-effects.
"Only available via veterinary wholesalers, the Cavalesse range of products will enable owners to protect their horses from the inside, whilst maintaining a healthy skin from the outside."
2ml of Cavalesse should be administered to horses and ponies weighing less than 500kg daily, while horses weighing more than 500kg should be given 3ml per day. Cavalesse Topical should be applied to the skin according to requirements.
For further information, please contact your Janssen Animal Health account manager or phone 01494 567555.
Janssen Animal Health is encouraging vets and nurses to think 'chicken' this spring.
According to the company, all the evidence suggests that there has been a massive increase in the number of people keeping a few chickens in their garden, resulting in a new breed of chicken owner who often has different expectations regarding healthcare, and views their birds as 'pets'.
Vet Nigel Underwood from Janssen Animal Health said: "It is very tempting for small animal practitioners to think that domestic poultry keepers are the preserve of large animal practices but it is very likely that many cat and dog owners will own chickens too and trust their vet to give them advice about the basic healthcare needs of all their pets."
This spring there is a big opportunity to make poultry owners aware of the need to worm their birds. The return of warmer weather can signal an increase in poultry worm numbers as the ambient temperature increases above 10 degrees centigrade and more worm eggs become infectious. Studies have shown that peak worm counts often coincide with peak chicken egg production. Unless chickens, turkeys and geese are de-wormed there is a risk that egg production could suffer, just when poultry keepers should be enjoying their best yields. Some may even notice smaller eggs and loss of shell and yolk colour. Birds may suffer weight loss, become anaemic or even die.
One study has shown that older birds are more likely to harbour worms and many domestic poultry keepers find themselves with an ageing flock because they allow their birds to live a full natural lifespan. Free range birds are also much more at risk of picking up parasitic worms because of increased exposure to the outdoors, more contact with wild birds and the opportunities to ingest intermediate hosts such as earthworms, beetles and snails.
Janssen Animal Health's Flubenvet® 60 gram pack is an in-feed treatment that, according to the company, is practical even for those with just a few hens in their garden. Flubenvet 60 gram contains enough wormer to treat around 20 chickens, with no egg withdrawal.
While worms are a year-round problem in poultry it is especially important to treat in the spring to tackle the increasing threat of worm infection. Thereafter, poultry owners will also get the best results if they continue to treat regularly in spring, summer and autumn, when new birds are acquired and before putting birds out to pasture. This helps to ensure that contamination of the chickens' environment with worm eggs is kept at a manageable level, reducing the risk of future infections.
Free client leaflets about worms affecting chickens, geese and turkeys are available by calling Janssen Animal Health on 01494 567555.
The British Veterinary Dental Association (BVDA) has signed a new agreement with Hill's Pet Nutrition which will provide support for the next three years.
The agreement comes after the previous period of sponsorship between the company and the BVDA reached the end of the three year term.
Lisa Milella, President, signed the agreement on behalf of the BVDA. She said: "Hill's has provided our organisation with invaluable support that will help us to continue to support the teaching needs of vets, undergraduates and nurses. We will also be able to ensure that dentistry is front of mind when thinking about the health and welfare of animals. Hill's has been a pleasure to work with over the last three years and I am very pleased to be renewing our agreement."
Adrian Pratt, Veterinary Affairs Manager at Hill's Pet Nutrition also welcomed the agreement, "Dentistry is an important source of revenue for practices and central to the wellbeing of pets. Both are priority areas where Hill's will be offering support, particularly during the current economic downturn. We are therefore very pleased to be able to confirm our association with the BVDA."
The agreement comes as the BVDA prepares to celebrate its 21st Birthday at BSAVA Congress in April. The satellite day event on the 1st April promises to be a 'must' for anyone interested in veterinary dentistry, with state of the art lectures that will illustrate how far the craft of dentistry has developed in the last 21 years.
The key note lecture, 'Magical MTA!*' will be delivered by Phil Thomson, Registrar at Birmingham Dental School, using a video linked operating microscope to illustrate how this gold standard endodontic treatment can be implemented. Additional lectures include oro-facial tumours, reconstructive surgery, radiotherapy and an active debate is promised on the topic of feline chronic gingivostomatitis. The meeting is open to members and non-members. Further details and registration are available by contacting Lisa Milella on telephone 01923 349690 or at lisa@milella.fsnet.co.uk.
*Mineral Trioxide Aggregate - MTA - a root canal repair material that allows natural healing and repair of dental tissues of otherwise unsalvageable teeth.
The RCVS issued a reminder today that there is just over a month left before the 1 April deadline for all veterinary practice premises from which medicines are to be supplied to be registered with the College.
Just over 4,500 premises have applied for registration since November 2008. This includes about 750 premises not previously listed with the College, demonstrating the usefulness of the process, which will enable the government to fulfil its obligations under European law to maintain and improve traceability of, and accountability for, veterinary medicines.
From 1 April it will be an offence for a veterinary surgeon to supply a veterinary medicinal product from any practice premises not registered with the RCVS. On conviction, those committing the offence may be liable to prosecution, which may include a fine or prison sentence. Veterinary surgeons convicted of criminal offences are also considered by the College's Preliminary Investigation Committee to decide whether the conviction would affect the individual's fitness to practise and should be referred to the Disciplinary Committee.
In addition to ensuring their practice premises are registered, veterinary surgeons also need to keep a record of other places where medicines are stored, so these can be considered during an inspection - such as vets' homes or cars, or perhaps a charity premises from which veterinary work is carried out and where medicines are stored. Such records will not be published, although some of those premises may need to be registered in their own right.
Practices accredited under the RCVS Practice Standards Scheme will be inspected by the RCVS; non-compliance with medicines standards will be dealt with under the rules of the Scheme. The Veterinary Medicines Directorate (VMD) will carry out inspections of other registered premises to ensure compliance with the Veterinary Medicines Regulations. Where non-compliance is noted, the VMD will take a proportionate enforcement approach ranging from issuing advice to, where appropriate, serving an improvement notice or seizing medicines.
VRCC the Essex-based veterinary referral specialists and centre for the treatment of cancer in dogs and cats has become the first in the UK to offer a canine melanoma vaccine.
The vaccine, previously only available in the U.S. where it has been granted a conditional license by the USDA, has been made available to VRCC's Head of Oncology Dr Susan North who fulfils the US Academic Credentials required.
According to VRCC, most oral tumours are not noticed early by owners, so many go undiagnosed and untreated until they are advanced and the dog has a poor chance of recovery.
Canine melanoma is an aggressive neoplasm treated with surgery and/or radiation therapy, which readily metastasises to the lymph nodes, liver, lungs and kidneys but is chemo-resistant. There is little evidence that chemotherapy improves survival time.
The canine melanoma vaccine develops effective immunotherapy in dogs that recognises and targets specific antigens on melanoma cells and may account for long-term tumour control and survival.
The vaccine is indicated for dogs with stage II or stage III oral melanoma for which local disease control has been achieved: negative local lymph nodes or positive lymph nodes that were surgically removed or irradiated.
The conditional license was granted based on the reasonable expectation that when used along with surgery and/or radiation therapy to treat the initial tumour the vaccine may help extend survival time and improve quality of life in dogs with canine oral melanoma.
US research concluded that canine patients with advanced disease have a median survival time of less than 5 months with standard therapies. In initial trials, dogs receiving the vaccination sequence had a median survival time of 389 days.
A canine transdermal device is especially matched to the vaccine for needle-free delivery and optimal distribution. Veterinary surgeons with a patient with oral melanoma should contact Dr Susan North at VRCC, www.vrcc.co.uk to discuss the case at an early stage, as initial treatment is important to ensure suitability for the vaccine.
Vetoquinol is advising vets and farmers to be on the lookout following the discovery of counterfeit Marbocyl on two farms in Northern Ireland.
The counterfeit product contains an unapproved source of Marbofloxacin in an untested formulation which presents an unknown risk to animal and human health if used.
Vetoquinol has informed the national authorities about this situation. It is illegal either to sell or supply the product or to knowingly buy and/or use it.
The withdrawal period of this counterfeit product is unknown. Should the product be used it could be detected in milk or after slaughter. Vetoquinol advises the veterinary community to be aware of the risk, to carefully check the product packaging before use and to continue to source the product from reputable suppliers.
Vetoquinol urges vets and farmers to take the following actions if you find this product on farm or are approached to purchase it:
Vetoquinol says vets can rest assured that it will do all that is necessary to remove this product from the market.
If you need further information or advice, do not hesitate to contact Vetoquinol on 0800 1698197.
Birds at two Bernard Matthews breeder sites in Suffolk and Norfolk have tested positive for avian influenza, though not the highly pathogenic H5 or H7 types.
A movement restriction has been put in place by DEFRA, but a cull has not so far been required. The BBC has the full story at: http://news.bbc.co.uk/1/hi/england/7912529.stm
Merial has announced that a recent change of licence means you can now administer the new generation NSAID, Previcox® for the relief of post operative pain associated with soft tissue and orthopaedic surgery in dogs.
Mark Riggs MRCVS, Veterinary Technical Advisor for Merial said: "Previcox (firocoxib) is now licensed for the relief of post operative pain. Oral PREVICOX can be administered starting 2 hours prior to surgery and has a rapid onset of action reaching peak plasma levels within 90 minutes. The palatable tablet can be given without food and is a realistic option which should be seriously considered when choosing pain relief for surgical patients.
"Containing the active ingredient firocoxib, Previcox is also highly COX-2 selective, being 380 times more selective for COX-2 than COX-1. As a result, it offers a highly desirable efficacy and safety profile which is particularly beneficial in cases which have gone through the additional stress of surgery.
"The recently published study by John P. Punke et al strengthens the evidence reinforcing the benefits offered by firocoxib. The research evaluated the in-vivo effects of firocoxib, meloxicam and tepoxalin in target tissues of dogs suffering with chronic osteoarthritis.
"Eight dogs were used in the cross-over study and each dog received each of the treatments (and a placebo) for seven days, with an appropriate wash out period in between. Firocoxib significantly reduced inflammatory mediators within blood and synovial fluid at all time points, whereas meloxicam only showed a significant reduction compared to baseline values at day four.
"With evidence demonstrating the speed of the anti-inflammatory effect of firocoxib, it may be time for vets to reconsider their post operative pain management. Previcox can be administered orally prior to surgery and can be given once daily for up to three days post operatively. For orthopaedic surgery this treatment schedule can be extended after the first 3 days upon judgement of the attending vet."
For further information please contact your local territory manager or call the Merial Customer Support Centre on 0845 601 4236.
The invaluable work done by equestrian vets in the UK is to be recognised with a new award sponsored by leading equine insurance provider Petplan Equine at the Animal Health Trust Awards in November. The ‘Petplan Equine Vet of the Year' award people's vote will reflect the huge contribution made by vets to the equine community.
Owners and riders will be able to nominate their equine vet for the award if they feel that they are deserving of the recognition that this accolade would bring. Veterinary practice personnel are also encouraged to nominate a colleague who they feel has gone beyond the call of duty. Leaflets have been sent to practices across the UK outlining how to nominate and people can also register through the Petplan Equine website www.petplanequine.co.uk. A short list will be drawn up from the nominations received and an independent panel will decide the winner, who will receive his or her award at the Animal Health Trust Equestrian Awards in London on November 6th 2008.
This year marks the 20th anniversary of the Animal Health Trust Equestrian Awards, which recognise the outstanding achievements made by horses, riders, owners and trainers throughout the equestrian world. This milestone coincides with Petplan Equine's 20th anniversary and, since 1994 when the Petplan Equine Charitable Trust was founded, it has raised over £5 million, almost £500,000 of which has been donated to the AHT to fund research and development.
Jo Whitaker of Petplan Equine says: "It has been a privilege to be involved with the AHT Awards over the years and we look forward to this exciting 20th anniversary year. Petplan Equine has sponsored the Eventing Award for the past three years but this new award will recognise the commitment and hard work of people within the equine veterinary profession and the service they provide to horse owners. Horse welfare is paramount at Petplan Equine and we are committed to promoting responsible horse ownership, through our wide range of policies, our charitable contributions and our Horse Handbook. This award will give the equine community the opportunity to acknowledge and celebrate the vet who has made the most outstanding contribution to the care of horses."
To nominate go to www.petplanequine.co.uk. The closing date for nomination is 3rd October 2008.
Epiphen, Vétoquinol's canine anti-epileptic drug, has been re-launched with new packaging and a useful dosing syringe.
"Some of our customers reported that they were having difficulty administering the drops accurately," explains Slavica Sobot, Product Manager. "So with this in mind, we have introduced a new plug-on syringe which will make it even easier for pet owners to dose accurately. The syringe will prevent the risk of inaccurate dosing through ‘flooding' from the dropper."
For more information, please call the Vétoquinol help line on 0800 169 8197 or contact your Vétoquinol representative.
In the most recent Petplan Pet Census, an annual study of pet ownership in the UK, 97% of vets reported that a lack of funds had led to owners choosing euthanasia over treatment.
Whilst some cases are the result of one-off ‘emergency' treatment, manageable long-term conditions are often at the root of much unnecessary euthanasia because owners simply cannot afford the cost of ongoing treatment. Reported increases in pet obesity and diabetes, arthritis and behavioural problems have all been cited in the Pet Census as common causes of increased and ongoing vet bills.
Vets have been reporting a rise in diseases that are related to obesity in companion animals for some time and with the Petplan Pet Census panel of almost two hundred (198) UK veterinary practices reporting that more than one third (36%) of all dogs and one quarter (29%) of cats they treat are obese, the future for many pets looks bleak. More than half (53%) of vets say that cases of cat and dog diabetes are on the increase. Obesity is actually bucking the trend of more historically significant diseases, including kennel cough and feline leukaemia, which are either remaining static or decreasing.
The number of pets with behavioural problems is also on the rise, with more than half of vets (55%) reporting an increase and most (95%) practices offering support for these animals. Effective treatment is not a quick-fix solution and requires changes to the owner's lifestyle and lengthy work with experts in the field.
Petplan Vet of the Year, Brian Faulkner said: "I think it is a common misconception that the predicament forcing pet owners to euthanase their pet is the out-of-the-blue, one-off vet fees for emergencies. But in fact we are noticing that owners whose pets have on-going illnesses such as diabetes and even behavioural problems that are very manageable are being faced with the dreadful decision to have to euthanase than face the ongoing financial burden. It's even more devastating when the owners have actually taken out an insurance policy but the nature of the policy only covers treatment of any one condition for up to one year. I always advise people to make sure their policies do not cap the time period over which any one condition is covered to avoid this very problem as more comprehensive insurers are then unable to offer cover on a pre-existing condition."
Simon Wheeler, Head of Marketing at Petplan, said: "We receive over 8,700 claims per week and of the top ten claims, six could be recurrent manageable conditions, such as diabetes or arthritis - the very animals that are currently most at risk of being euthanased."
Research announced simultaneously by Sainsbury's Finance has reached similar conclusions. Sainsbury's found that:
Sainsbury's believes that there are two main reasons for this tragic problem: advances in veterinary care leading to increased costs, and the large number (55%) of pets that remain uninsured.
Ed's note: Isn't it time that pet insurance became compulsory?
Emily Holbrook MRCVS, Garth Tozer MRCVS, Dr Richard Dixon and Ken Davison MRCVS have all won a Best Practice Employer Award from Novartis Animal Health after glowing nominations from the staff at their practices.
In addition, Katherine Corbett VN from Nine Lives Veterinary Centre won a special new award, worth £500, for the veterinary nurse that in the judges' opinion had best used the opportunities given to her by her boss, Emily Holbrook.
Katherine's first question when told of her win really demonstrates the commitment that veterinary nurses will give a good boss: "Can I spend it on buying one of Kruuse's Buster ICU cages for the practice? Emily has given me so much; I'd love to give something back."
Rachel Smithson, Marketing Manager at Novartis said: "All of our winners were asked what steps they take to ensure a happy team. Their answers were almost unanimous. Empower your staff. Give them responsibility, and if that means accepting the occasional mistake, then do so. Praise them for a job well done. Thank them regularly. Not only will it make your practice a better working environment, but as Katherine demonstrates, your staff will probably go to extraordinary lengths to support you. That translates into a more profitable practice, and higher standards of veterinary care."
The story is covered in full in the August and September editions of Veterinary Practice magazine, downloadable from www.vetsurgeon.org
Sarah Palmer (left) of Novartis Animal Health makes the presentation to head nurse Katherine Corbett and veterinary surgeon Emily Holbrook of Nine Lives Veterinary Practice; behind them are Anne Corbett (receptionist), Lindsay Harrison (nursing assistant), and Laura Steele (veterinary surgeon).
Kenneth Agnew from Novartis Animal Health prepares to present Kenneth Davison with his Best Practice Employer Award, whilst the team toast their boss.
Veterinary Nursing Assistant Abby Brown (left) and Abby Roberts from Novartis Animal Health toast Garth Tozer, Novartis Best Practice Employer Award winner.
Donna Lewis (BVNA), and Novartis Animal Health CEO George Gunn present Dr Richard Dixon with his award.
Boehringer Ingelheim has announced the results of an independent three-year study which demonstrates that dogs suffering from the most common type of heart failure lived longer (average time in the study of 267 days vs. 140 days) when treated with the product Vetmedin (pimobendan) compared with the ACE inhibitor benazepril hydrochloride.
According to Boehringer, results from the QUEST (Quality of Life and Extension of Survival Time) study, published in the September/October 2008 issue of the Journal of Veterinary Internal Medicine, mark a significant milestone in canine cardiac health.
25% of all small to medium-sized dogs over the age of seven are likely to suffer from heart disease at some point in their life, and 75% of those cases are caused by myxomatous mitral valve disease (MMVD), sometimes known as "valvular insufficiency" or "endocardiosis".
Adrian Boswood from the Royal Veterinary College, London, a Veterinary Cardiology Specialist and a lead-investigator on the study, said: "With QUEST demonstrating that dogs treated with Vetmedin live on average nearly twice as long as those on benazepril, it is now time for us as veterinary cardiologists and practising veterinarians to look again at how we are treating our patients suffering from this serious condition."
Dr. Michael O'Grady from the Ontario Veterinary College, University of Guelph, a fellow lead-investigator added, "The QUEST study provides compelling evidence that dogs with the most common form of heart failure should be receiving Vetmedin® as an essential part of their treatment regimen."
QUEST is the largest international study ever conducted looking at treatment for congestive heart failure (CHF) caused by MMVD, with 260 dogs studied in 11 countries, across three continents, over a period of three years.
The study was conducted by a team of 32 independent veterinary cardiologists from Australia, Canada, France, Germany and the United Kingdom among other countries.
For more information on the QUEST study and on CHF caused by MMVD, see http://www.questtrial.com/
Merial has launched a new website where you can test your NSAID knowledge and get the chance to win a £50 book voucher. There’s a new winner every month.
The website, http://www.osteoarthritisindogs.co.uk is designed to help practice staff understand more about canine osteoarthritis (OA) and effective management of the condition. The site covers every aspect of canine OA, including treatments and non-pharmacological management strategies. There is also a section for dog owners where practice staff can direct their customers for further information.
Merial product manager Claire Parry-Baggott said: “The practice section is password protected but registration is quite straightforward. The test itself consists of 10 multi-choice questions and your test results are returned within a matter of a few seconds.”
Claire added: "Canine osteoarthritis is a challenging area on its own but is further complicated by the choice of NSAIDs that serve the market. All NSAIDs inhibit the COX-2 enzyme which plays the key role in the development of pain and inflammation. However, traditional NSAIDs also inhibit COX-1 to widely varying degrees. This is a beneficial enzyme that plays an important role in normal physiological functioning. The resulting unwanted side-effects of COX-1 inhibition may hinder therapy, however this is not yet recognised by many vet practices.
“This site will help vets and practice staff better understand canine OA, whilst giving a clearer picture of how different NSAID’s interact with COX-1 and COX-2. The new generation NSAID – firocoxib (Previcox®), selects COX-2 whilst sparing COX-1 and so is a real step forward in the treatment of canine OA.”
The first coxib for the treatment of osteoarthritis (OA) in dogs, PREVICOX® (Merial), has now been licensed for the relief of post-operative pain and inflammation following soft tissue surgery.
"PREVICOX is the first coxib specifically designed for dogs, and now vets have another reason to use it," said product manager Claire Parry-Baggott. "In addition to the osteoarthritis claim, it is now also proven for use following soft tissue surgery with no adverse effect on bleeding times, haematology or biochemistry.
She added: "With its rapid onset of action and once daily dosing vets can prescribe PREVICOX with confidence at a dose rate of 5mg/kg, two hours pre-surgery and for up to three days including the day of surgery".
To help practice staff explain the importance of the owner's role in after surgery care, and the benefits of using PREVICOX, Merial has produced a practice guide for dog owners following soft tissue surgery. The guide deals with all areas of surgery aftercare including dietary advice, post surgery exercise and wound care. For copies, please contact your local Merial Territory Manager, or call 0870 6000 123.
Defra has announced the detection of Bluetongue in 18 imported cattle on premises near Bishop Auckland, County Durham. The animals originated from within the BTV8 Restricted Zone in Germany and were detected as a result of post-import testing carried out by Defra on all Bluetongue susceptible animals arriving from Continental Europe.
This is the fourth incidence of infected animals being imported to the UK. Alongside the premises in East Sussex, Hertfordshire and Devon identified in August, the imported animals will remain under restrictions.
As of 1 September the whole of England and Wales is now in a Protection Zone and approximately 30 million doses of vaccine have so far been made available to farmers throughout England and Wales to protect their stock. However, it may take up to six to eight weeks from now for livestock keepers in the North of England and Wales to have had sufficient opportunity to vaccinate their livestock and to gain immunity (at least three weeks in sheep, and six weeks in cattle).
To allow livestock keepers in those areas sufficient opportunity to protect their animals, and while further veterinary investigations are carried out, these particular infected animals will remain under restriction until late October. Any further positive import cases detected may also be restricted for a period of time depending on veterinary risk assessment, while vaccination continues.
Deputy Chief Veterinary Officer, Alick Simmons said: "This incident shows how important it is for farmers to consider potential disease risks when buying stock, regardless of source. Buyers need to consider how best to protect their own businesses and those of their neighbours and make sure they are clear about the stock they are intending to buy.
"I also want to remind farmers about the importance of vaccination. It is the only effective tool to protect susceptible animals from Bluetongue. Recent evidence indicates a drop or delay in vaccine take-up in counties recently brought into the Protection Zone. Sales data for some of those counties suggest that the number of animals vaccinated in these areas could be as low as one in three, and in Northumberland and Cumbria, the most recent counties brought into the Protection Zone, as low as one in five.
"The threat from Bluetongue is present and real, as shown by the most recent import cases. Vaccination as a preventive measure is therefore more important than ever, so the message to the industry remains clear: don't hesitate, vaccinate".
Pfizer Animal Health has confirmed that the agreement to acquire multiple product franchises from the Schering-Plough Corporation has been completed - and approved by the European Commission. Pfizer has acquired these assets for approximately euro 116 million in cash.
The agreement covers all European Union countries and the franchises include all major animal health species including cattle, swine, equine and companion animal. Pfizer executives say the agreement leaves them with the most in-depth coverage of therapeutic areas, and the most highly recognised brands, in the industry. Precise details of the agreement are not being released although additional information on the products concerned will be the subject of further announcements in due course.
Pfizer has acquired certain rights to the following products in the European Economic Area:
Albert Bourla, President of Pfizer Animal Health in Europe, said: "This represents a significant expansion of our product portfolio and strengthens our long term commitment not just to veterinary surgeons, but also to farmers and pet owners. Pfizer spends hundreds of millions of dollars on research and development every year, and brings more new products to market than any other company, but when the opportunity arose to add well known, well respected brands to a portfolio that is already extremely strong, we had little hesitation in taking it."